CURRICULUM VITAE

Mahmoud Abuhamda, MD

Clinical Research Coordinator
North Star Medical Research, LLC

MIA Mahmoud 24OCT2017

North Star Medical Research, LLC
18660 Bagley Road,
Building II, Suite 205
Middleburg Heights, OH 44130

Telephone: +01 440 234 5700
Fax: +01 440 234 5710
email: mabuhamda@northstarresearch.org

EDUCATION:

Ross University School of Medicine, Commonwealth of Dominica	M.D.	8/08 – 5/16	Medicine
Cleveland State University, Cleveland, OH	Post-Baccalaureate Studies	5/06 - 8/08	Neuroscience and Molecular Biology
Cleveland State University, Cleveland, Ohio	B.S.	9/76 - 6/82	Biology

POSITIONS:

08/15– Present North Star Medical Research, LLC., Clinical Research Coordinator, Middleurg Heights, OH
04/13 –08/15 University Hospitals of Cleveland, Lab Technician and Phlebotomist CORE, Cleveland, OH
01/04 –12/08 University Hospitals of Cleveland, Lab Technician and Phlebotomist Pathology Dept. Cleveland, OH

TRAINING:

Good Clinical Practice (GCP)
Blood Born Pathogens
Health Insurance and Privacy Accountability Act (HIPPA)
IATA Certified Handing Biological Substances
Certified in EDC Entry
Certified in ECG Acquisition

INDUSTRY SPONSORED RESEARCH:

A phase II/III randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of intravenous neridronic acid in subjects with complex regional pain syndrome type I (CRPS-I).

A Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of ALKS 5461 in adult outpatients with Major Depressive Disorder.

A phase III, double-blind, randomized, multicenter, placebo-controlled study to evaluate the efficacy and safety of TNX-102 SL taken sublingually at bedtime in patients with Fibromyalgia.

A national, randomized, 12-week, double-blind, placebo-controlled study to assess the safety and efficacy of plecanatide (3.0 and 6.0 mg) in patients with chronic idiopathic constipation.

A multicenter, randomized, double-blind, placebo-controlled, Fluoxetine-referenced, parallel-group study to evaluate the efficacy, safety and tolerability of Desvenlafaxine Succinate Sustained Release (DVS SR) in the treatment of children and adolescents outpatients with Major Depressive Disorder.

A six month, open label, multi-center, flexible dose extension study to the B2061014 study to evaluate the safety, tolerability and efficacy of Desvenlafaxine Succinate Sustained Release (DVS SR) tablest in the treatment of children and adolescent outpatients with Major Depressive Disorder.

A randomized, double-blind, placebo and active-controlled study of DS-5565-A-E310 in subjects with pain associated with Fibromyalgia.

An open-label extension study of DS-5565-A-312 for 52 weeks in pain associated with Fibromyalgia.

A phase IIb, double-blind, randomized, multicenter, placebo-controlled study to evaluate the efficacy and safety of study drug taken sublingually at bedtime in patients with Fibromyalgia.

A 12-month, multicenter, open-label extension study to evaluate the long-term safety of TNX-102 sublingual tablets taken daily at bedtime in patients with Fibromyalgia

A multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of fixed-dose once-daily oral aripiprazole in children and adolescents with Tourette's Disorder.

An open-label, multicenter study evaluating the safety and tolerability of once-daily oral Aripiprazole in children and adolescents with Tourette's Disorder.

A phase III, multicenter, randomized, double-blind, parallel-group, placebo-controlled, dose-optimization study to evaluate the efficacy, safety, and tolerability of study drug in adults aged 18-55 years with moderate to severe Binge Eating Disorder.

A phase III, multicenter, open-label, 12-month extension safety and tolerability study of SPD489 in the treatment of adults with binge eating disorder.

A randomized, double blind, placebo-controlled evaluation of MF4637 for correcting the Omega-3 nutritional deficiency in NAFLD patients when added to standard of care.